Central regions | Technology & innovation

New tuberculosis drug with proven efficacy developed

7 Mar '18
Infectex, a Russian biomed company, has come up with a new drug candidate, designated SQ109, which is unparalleled elsewhere in the world, as the developers said. Clinical trials for the candidate were completed in 2017. Infectex claims this is the first new proven drug for tuberculosis in the global market in four decades.

The 2b-3 phase clinical trials were conducted in seven clinical centers in Russia and took six months. A reported 140 patients completed active therapy and showed quantifiable improvements.

The SQ109 is reported to have demonstrated safety, efficacy, and good tolerance. Tests have proved that by the end of the sixth month the SQ109-testing patient group, combining the candidate with conventional therapy, showed an up to 80% bacterial generation reduction rate, compared to 61% in a conventional approach plus placebo.

The SQ109 is a small 1,2-ethylenediamine molecule which is said to possess three unique action mechanisms that differ from those of other antibiotics used in tuberculosis therapy.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content

Locations: Moscow

Tags: tuberculosis (7) / Infectex (2) / clinical trials (12) / Sergei Borisov (0) / SQ109 (0) /

Latest News: Central regions
14 Mar '18 | Finance, business | Retail, FMCG
13 Mar '18 | Finance, business | Technology & innovation
12 Mar '18 | Finance, business | Technology & innovation
7 Mar '18 | Technology & innovation
28 Feb '18 | Technology & innovation | Finance, business

Feature stories

21 Nov '17
Russian scientists have come up with what they say is...
7 Sep '17
26 Jul '17
Scientists at Tomsk Polytechnic (TPU) in Siberia have...
Search (News archive - 21221)
Independent Software Developers Forum
Marchmont News

Latest News

22 Mar '18
A new Fund for Creative Economy has started operation...
21 Mar '18
Siberian scientists have discovered what they call a...
19 Mar '18
New catalysts have been developed which are said to...

Most read stories from last week

22 Mar '18
A new Fund for Creative Economy has started operation...